名稱 | BCR-ABL1 A337V/BaF3 |
型號(hào) | CBP73288 |
報(bào)價(jià) | ![]() |
特點(diǎn) | BCR-ABL1 [E255V]/BaF3,母細(xì)胞:BaF3 |
產(chǎn)品搜索
相關(guān)文章
- NCRI:新型檢測技術(shù)或能提前8年診斷出食管癌
- 新型冠狀病毒:用于診斷的假病毒標(biāo)準(zhǔn)品和用于藥物研發(fā)的假病毒模型
- 血液系統(tǒng)惡性腫瘤治療研究熱點(diǎn)
- NIPT標(biāo)準(zhǔn)品-助力無創(chuàng)產(chǎn)前檢測
- *針對肝癌的PD-1抗體獲FDA批準(zhǔn),國產(chǎn)PD-1抗體進(jìn)入三期
- CSF3R細(xì)胞篩選模型
- 細(xì)胞株的一些篩選事項(xiàng)為您解讀
- 真實(shí)的“藍(lán)瘦香菇”長這樣
- HPV分子診斷標(biāo)準(zhǔn)品擴(kuò)容:精準(zhǔn)檢測,實(shí)力升級(jí)
- IL10及其受體細(xì)胞篩選模型
聯(lián)系我們
電話:4008750250
號(hào)碼:
手機(jī):18066071954
地址:南京市棲霞區(qū)緯地路9號(hào)
Email: zhangxiangwen@cobioer.com
產(chǎn)品展示 / PRODUCTS
藥靶細(xì)胞株 > kinase激酶細(xì)胞株 > CBP73288BCR-ABL1 A337V/BaF3

- 詳細(xì)內(nèi)容
CBP73288 | |
I. Introduction | |
Cell Line Name: | BCR-ABL1 [E255V]/BaF3 |
Host Cell: | Ba/F3 |
Stability: | 16 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
Application: | Anti-proliferation assay and PD assay |
Freeze Medium: | 90% FBS+10% DMSO |
Complete Culture Medium: | RPMI-1640+10%FBS |
Mycoplasma Status: | Negative |
II.Background | |
Presence of a BCR-ABL1 fusion gene is necessary for the pathogenesis of CML. In up to 95% of cases, a t(9;22) (q34;q11) translocation results in the BCR-ABL1 fusion gene (Faderl et al. 1999). This translocation results in the Philadephia chromosome. In rare CML cases lacking the traditional t(9;22) translocation, other translocations result in the creation of the BCR-ABL1 fusion gene, which sometimes involve multiple chromosomes. ABL1 is a tyrosine kinase, and, in normal cells, it plays a role in cellular differentiation and regulation of the cell cycle. The BCR-ABL1 fusion gene creates a constitutively active tyrosine kinase, which leads to uncontrolled proliferation. | |
III. Representative Data | |
1. WB of BCR-ABL1 [E255V]/BaF3 | |
2.Sanger of BCR-ABL1 [E255V]/BaF3 Figure 2. BCR-ABL1 E255V Figure 3. BCR-ABL1 [E255V]/BaF3 Fusion | |
3. Anti-proliferation assay Figure 4. CTG Proliferation Assay of BaF3 BCR-ABL1 E255V Cells (C1). | |